Literature DB >> 24158017

LDL but not HDL increases adiponectin release of primary human adipocytes.

Sabrina Krautbauer1, Markus Neumeier, Kristina Eisinger, Yvonne Hader, Ashraf Dada, Gerd Schmitz, Charalampos Aslanidis, Christa Buechler.   

Abstract

Adipocytes in obesity have inappropriately low cholesterol while adiponectin release is reduced. Cholesterol shortage may contribute to low adiponectin and 3T3-L1 cells treated with lovastatin have diminished adiponectin in cell supernatants. LDL and HDL deliver cholesterol to adipocytes. LDL but not HDL increases adiponectin in cell supernatants of primary human adipocytes. The effect of LDL is not blocked by receptor associated protein suggesting that members of the LDL-receptor family are not involved. To evaluate whether these in vitro observations translate into changes in systemic adiponectin, adiponectin was measured in serum of three patients before, immediately after and 3d after LDL-apheresis. Whereas circulating lipoproteins are reduced immediately after apheresis adiponectin is not changed. Therefore, acute lowering of lipoproteins does not affect systemic adiponectin also excluding that plenty of adiponectin is bound to lipoprotein particles. Accordingly, levels of adiponectin in purified lipoproteins are quite low. Familial hypobetalipoproteinemia (FHBL) is a rare disorder associated with low plasma LDL. Serum adiponectin is, however, similar compared to healthy controls. Thus, neither LDL nor HDL directly contributes to circulating adiponectin concentrations.
© 2013.

Entities:  

Keywords:  Familial hypobetalipoproteinemia; LDL apheresis; Lipoprotein

Mesh:

Substances:

Year:  2013        PMID: 24158017     DOI: 10.1016/j.yexmp.2013.10.002

Source DB:  PubMed          Journal:  Exp Mol Pathol        ISSN: 0014-4800            Impact factor:   3.362


  4 in total

Review 1.  Drugs Involved in Dyslipidemia and Obesity Treatment: Focus on Adipose Tissue.

Authors:  Sofia Dias; Sílvia Paredes; Laura Ribeiro
Journal:  Int J Endocrinol       Date:  2018-01-17       Impact factor: 3.257

Review 2.  Statin Treatment-Induced Development of Type 2 Diabetes: From Clinical Evidence to Mechanistic Insights.

Authors:  Unai Galicia-Garcia; Shifa Jebari; Asier Larrea-Sebal; Kepa B Uribe; Haziq Siddiqi; Helena Ostolaza; Asier Benito-Vicente; César Martín
Journal:  Int J Mol Sci       Date:  2020-07-02       Impact factor: 5.923

Review 3.  Emerging Insights on the Diverse Roles of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) in Chronic Liver Diseases: Cholesterol Metabolism and Beyond.

Authors:  Thomas Grewal; Christa Buechler
Journal:  Int J Mol Sci       Date:  2022-01-19       Impact factor: 5.923

4.  Impact of selective LDL apheresis on serum chemerin levels in patients with hypercholesterolemia.

Authors:  Viktória E Varga; Hajnalka Lőrincz; Noémi Zsíros; Péter Fülöp; Ildikó Seres; György Paragh; József Balla; Mariann Harangi
Journal:  Lipids Health Dis       Date:  2016-10-18       Impact factor: 3.876

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.